ClinicalTrials.gg
CompletedNCT03366688Updated Dec 21, 2020

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

A Phase 1 interventional study of IBI306 and placebo in Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
43rd of 53
58 · median 207
Started
2017
with 1 other
Phase 1
12 of 59
2 open now
Registered
15th of 59
by date
Lead sponsor
4 of 59
Innovent Biologics (Suzhou) Co. Ltd.

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 43rd largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2017, is one of 12 in phase 1, and was the 15th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C)uptake. This is a randomized, double-blind, placebo-controlled,single ascending dose study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and immunogenicity of IBI306 in healthy adults.

Read the detailed description

Ascending dose design includes 6 dose levels (25 mg, 75 mg, 150 mg, 300 mg, 450 mg and 600 mg). Tolerance and safety data up to 14 days after dosing from all subjects of the previous cohort will be reviewed before proceeding to the next dose. Total duration of the study per subject is 12 weeks.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese healthy men or women aged 18 to 55 years old at screening (inclusive);
  • Serum LDL-C concentration between 1.8 mmol/L and 4.9 mmol/L (inclusive)at screening;
  • between 19 and 28 kg/m2 (inclusive);
  • Willing to maintain the current regular diet and physical activity;
  • Female subjects and male subject's partner who could become pregnant should take effective contraceptions during the treatment period and 6 months after dosing;
  • Without any medical history of serious diseases;
  • Willing to comply with protocol required visit schedule and visit requirements and provide written .

Exclusion criteria

Exclusion Criteria:

  • Breast-feeding or pregnant women;
  • History of allergic reaction;
  • Previously received any anti-PCSK-9 treatment;
  • Vital signs, physical examination, clinical laboratory test, 12-lead , and chest X-ray are abnormal with clinical significance;
  • Not willing to stop intense physical activities (such as weight lifting or long-distance running) before 72 hours of the scheduled visits;
  • Any hospitalization within one month before screening, or major surgery within six months before screening, or any other unstable medical condition;
  • Received an chemical agent within 30 days before dosing;
  • Received an investigational biological agent within 90 days before dosing;
  • Use of medications including over-the-counter medication within 14 days or less than 5 half-lifes of the agent;
  • Use of herb,vitamins or nutraceutical in order to alter serum lipids;
  • Positive screen of surface antigen, virus, or syphilis infection at screening;
  • History or clinical evidence of alcohol or drugs of abuse within 12 months before screening;
  • With any consumption of alcohol and caffeinated beverages within 72 hours prior to and during the trial;
  • Blood donations or blood loss 200 ml and more within 2 months before screening;
  • History of organ transplantation or malignant tumor;
  • Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Active comparator
    IBI306

    Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design

    Drug: IBI306

  • Placebo comparator
    placebo

    Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design

    Drug: placebo

Interventions

  • DrugIBI306

    Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

  • Drugplacebo

    Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events(AEs) as assessed by the criteria of National Institute on Aging

    Time frame: up to 12 weeks

Secondary outcomes

  1. The area under the curve (AUC) of serum concentration of the drug after the administration

    Time frame: up to 12 weeks

  2. Maximum concentration (Cmax) of the drug after the administration

    Time frame: up to 12 weeks

  3. Time at which maximum concentration (Tmax) occurs for the drug after the administration

    Time frame: up to 12 weeks

  4. The half-life (t1/2) of drug after the administration

    Time frame: up to 12 weeks

  5. Assessment of serum concentrations of PCSK-9

    Time frame: up to 12 weeks

  6. Change from baseline in lipid parameters

    Time frame: up to 12 weeks

  7. Number of participants with anti-drug antibodies or neutralizing antibodies

    Time frame: up to 12 weeks

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol with any amendments and statistical analysis plan. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Nov 2018, 11 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 11 months is above that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 8, 2017
StartActual
Nov 27, 2017
Primary completionActual
Nov 5, 2018
CompletionActual
Nov 5, 2018
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03366688
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Nov 27, 2017
Primary completion
Nov 5, 2018
Completion
Nov 5, 2018
Last update
Dec 21, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion